GIEQs

📢 Registration is now open for GIEQs VII – Value for Money in Everyday Endoscopy.

🗓️ From 7–9 October 2026, GIEQs VII will bring together an international faculty in Ghent for a comprehensive programme focused on quality, education and innovation in gastrointestinal endoscopy.

The meeting includes:
✅ A hands-on pre-course on 7 October
✅ Two symposium days with parallel studios
✅ Live endoscopy sessions
✅ Interactive case discussions and real-time decision-making
✅ Live and virtual attendance options

Register before 1 September to take advantage of:
☑️ 25% Early-bird discount
☑️ A complimentary 1-year GIEQs PRO subscription with every live registration
☑️ An additional 20% discount for ESGE members
☑️ Group discounts for teams and departments

🔗 Learn more and register: https://www.gieqs.com/vii

Cold versus hot EMR is not simply a recurrence contest.

In a model based on 1,516 randomised lesions, cold EMR had more recurrence but less delayed bleeding and perforation. Across the six-month pathway it was approximately $287 cheaper per patient and marginally more effective.

The exact economics will differ in Europe, and the model made favourable assumptions about retreatment. The useful lesson survives: compare the entire pathway, not one procedural endpoint.

The GIEQs VII polypectomy masterclass will make that choice lesion by lesion.

https://www.gieqs.com/vii

The numbers that convince management.

One GIEQs VII session is built entirely around the business case for an EMR service: equipment and training as capital investment, revenue versus cost of an EMR list, and the throughput modelling that turns "we'd like to do this" into a proposal your manager will actually sign. Building the capability locally avoids the cost cascade of referring every complex polyp onward.

Value for money isn't only a clinical argument — it's a budget one. GIEQs VII makes both.

Early-bird 25% off until 1 Sep → gieqs.com/vii

A €20 stool test before a €500 endoscopy.

Faecal calprotectin has ~93% sensitivity for active IBD inflammation — enough to triage who actually needs a scope and who can be managed and monitored without one. Paired with intestinal ultrasound, it becomes a genuine gatekeeper: fewer surveillance endoscopies that change nothing, more capacity for the ones that do.

GIEQs VII's IBD sessions treat calprotectin and IUS as the value levers, they are — not as a way to avoid endoscopy, but to aim it.

Early-bird 25% off until 1 Sep → gieqs.com/vii

A blood test may be easier to offer. It is not yet a better colorectal cancer screening test.

In direct comparisons, pooled sensitivity for CRC was 36% with blood-based tests and 65% with FIT. For precancerous lesions, the corresponding figures were 15% and 29%. Current blood tests were also not cost-effective against FIT.

The immediate value question is therefore not "How do we replace stool?" It is "How do we make FIT easier to complete, return and follow up?"

That is the discussion in the FIT-based screening session at GIEQs VII.

https://www.gieqs.com/vii

There are worse places to spend two days than Ghent.

Medieval squares, a canal network you can walk in an evening, and one of the most underrated food scenes in Europe — Ghent is the kind of city where the conference dinner competes with the programme. It's also compact: hotels, restaurants and the GIEQs Studio are all within walking distance, and Brussels Airport is 30 minutes by train.

Come for the value-for-money endoscopy. Stay for the city.

Early-bird 25% off until 1 Sep → gieqs.com/vii

Calprotectin and intestinal ultrasound keep getting better. So is IBD endoscopy on the way out? Dr Jeroen Geldof (UZ Gent):

"Biomarkers such as faecal calprotectin and intestinal ultrasound have changed our approach to IBD monitoring. Nonetheless, endoscopy remains essential for early diagnosis and treat-to-target management."

The interesting question for your unit is when each tool earns its cost — and when a scope is the only answer. That is the IBD session at GIEQs VII: monitoring strategy through a value lens.

GIEQs VII · 7–9 October · Ghent · early-bird until 1 Sep → gieqs.com/vii

Hands-On Pre-Course, the resection bench: cold-snare polypectomy, clip closure, and loop & band ligation — the everyday skills, deconstructed on a box trainer before you're back on a real list.

Want the complex end? Step up to EMR and ESD on ex-vivo tissue at the neighbouring stations.

Wednesday 7 October, Ghent. Groups of three, individual feedback, 30 places, separate registration.

🔗 Register → gieqs.com/vii

"Better imaging, better techniques and better education are transforming lower GI endoscopy — allowing us to detect earlier, treat more precisely, and offer our patients the best outcomes we can."

Dr. Lobke Desomer (AZ Delta) works at exactly that intersection: optical diagnosis, cold snare technique and the training that makes both stick.

At GIEQs VII she brings it to the lower GI live studio — real lesions, real decisions, and the evidence for why precise beats aggressive.

GIEQs VII · 7–9 October · Ghent → gieqs.com/vii

Where does AI in endoscopy actually stand — approved tool or perpetual pilot study? Prof. Dr. Alanna Ebigbo (University Hospital Augsburg) draws the line precisely:

"AI devices have been approved in Europe for the detection and characterisation of early Barrett’s neoplasia, with the potential to improve dysplasia detection in the upper GI tract. For most other indications, these tools are still far from approval for everyday use."

At GIEQs VII he separates the AI applications you can defensibly buy today from the ones that are still research — with upper GI live cases to show the difference.

GIEQs VII · 7–9 October · Ghent · early-bird until 1 Sep → gieqs.com/vii